Abdominal obesity and digestive system cancer: a systematic review and meta-analysis of prospective studies.
Abdominal obesity
Digestive system cancer
Waist circumference
Waist-to-hip ratio
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
27 Nov 2023
27 Nov 2023
Historique:
received:
13
05
2023
accepted:
20
11
2023
medline:
29
11
2023
pubmed:
28
11
2023
entrez:
28
11
2023
Statut:
epublish
Résumé
The diagnostic criteria for abdominal obesity are usually waist circumference or waist-to-hip ratio. The magnitude of the risks for cancers of the digestive system and abdominal obesity is unknown. To assess whether abdominal obesity increases the risk of digestive cancer, we conducted a systematic review and meta-analysis of prospective cohort studies in a database. PubMed, Embase, and Web of Science databases were searched from their inception to December 2022. The 9-star Newcastle Ottawa Scale was used to assess study quality. Pooled relative risks and 95% confidence intervals were calculated using fixed or random effect models respectively. The stability of the results was explored by one-by-one exclusion. Subgroup analysis was conducted to explore sources of heterogeneity. Publication bias was evaluated by Begg's and Egger's tests. A total of 43 cohort studies were included. There were 42 and 31 studies in the meta-analysis of waist circumference and waist-to-hip ratio on digestive system cancer, respectively. The results of the meta-analysis revealed that the greater waist circumference and waist-to-hip ratio were correlated with increased incidence of digestive system cancers: waist circumference: RR 1.48, 95% CI 1.38-1.59, p < 0.001; waist-to-hip ratio: RR 1.33, 95% CI 1.28-1.38, p = 0.001. Subgroup analysis by cancer type showed that higher WC and WHR would increase the prevalence of LC, PC, GC, EC, and CRC. The sensitivity analysis was conducted by a one-by-one elimination method, and the results of the meta-analysis remained stable. It is proved that the results were robust by the trim-and-fill method. There was evidence to suggest that abdominal obesity increased the incidence of digestive cancer, it is necessary to take appropriate measures to reduce abdominal obesity. Waist circumference and waist-to-hip ratio may be better predictors of digestive system cancers. However, the association between waist circumference and digestive system cancer was greater, so more attention should be paid to measuring abdominal obesity with waist circumference.
Sections du résumé
BACKGROUND
BACKGROUND
The diagnostic criteria for abdominal obesity are usually waist circumference or waist-to-hip ratio. The magnitude of the risks for cancers of the digestive system and abdominal obesity is unknown. To assess whether abdominal obesity increases the risk of digestive cancer, we conducted a systematic review and meta-analysis of prospective cohort studies in a database.
METHODS
METHODS
PubMed, Embase, and Web of Science databases were searched from their inception to December 2022. The 9-star Newcastle Ottawa Scale was used to assess study quality. Pooled relative risks and 95% confidence intervals were calculated using fixed or random effect models respectively. The stability of the results was explored by one-by-one exclusion. Subgroup analysis was conducted to explore sources of heterogeneity. Publication bias was evaluated by Begg's and Egger's tests.
RESULTS
RESULTS
A total of 43 cohort studies were included. There were 42 and 31 studies in the meta-analysis of waist circumference and waist-to-hip ratio on digestive system cancer, respectively. The results of the meta-analysis revealed that the greater waist circumference and waist-to-hip ratio were correlated with increased incidence of digestive system cancers: waist circumference: RR 1.48, 95% CI 1.38-1.59, p < 0.001; waist-to-hip ratio: RR 1.33, 95% CI 1.28-1.38, p = 0.001. Subgroup analysis by cancer type showed that higher WC and WHR would increase the prevalence of LC, PC, GC, EC, and CRC. The sensitivity analysis was conducted by a one-by-one elimination method, and the results of the meta-analysis remained stable. It is proved that the results were robust by the trim-and-fill method.
CONCLUSIONS
CONCLUSIONS
There was evidence to suggest that abdominal obesity increased the incidence of digestive cancer, it is necessary to take appropriate measures to reduce abdominal obesity. Waist circumference and waist-to-hip ratio may be better predictors of digestive system cancers. However, the association between waist circumference and digestive system cancer was greater, so more attention should be paid to measuring abdominal obesity with waist circumference.
Identifiants
pubmed: 38012596
doi: 10.1186/s12889-023-17275-2
pii: 10.1186/s12889-023-17275-2
pmc: PMC10680266
doi:
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2343Informations de copyright
© 2023. The Author(s).
Références
Lancet. 2014 Aug 30;384(9945):755-65
pubmed: 25129328
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Int J Cancer. 2021 Mar 1;148(5):1144-1154
pubmed: 32955731
J Natl Cancer Inst. 2006 Jul 5;98(13):920-31
pubmed: 16818856
Cancer Causes Control. 2016 Mar;27(3):291-300
pubmed: 26759333
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
N Engl J Med. 2008 Nov 13;359(20):2105-20
pubmed: 19005195
Gut. 2012 Sep;61(9):1261-8
pubmed: 22174193
Int J Epidemiol. 2016 Jun;45(3):871-83
pubmed: 26403814
Emerg Themes Epidemiol. 2016 Jan 11;13:2
pubmed: 26759600
Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3252-61
pubmed: 18990768
World J Hepatol. 2015 Aug 18;7(17):2110-8
pubmed: 26301053
Br J Cancer. 2018 Oct;119(8):1018-1027
pubmed: 30327562
Cancer Causes Control. 2008 Sep;19(7):783-92
pubmed: 18322811
Br J Cancer. 2005 Nov 28;93(11):1310-5
pubmed: 16288300
United European Gastroenterol J. 2019 Nov;7(9):1250-1260
pubmed: 31700638
Eur J Cancer. 2006 Oct;42(15):2590-7
pubmed: 16914307
Pancreatology. 2019 Oct;19(7):941-950
pubmed: 31447281
Int J Obes (Lond). 2012 Jan;36(1):107-18
pubmed: 21427695
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Int J Cancer. 2015 Aug 1;137(3):646-57
pubmed: 25598323
Int J Cancer. 2020 Aug 1;147(3):675-685
pubmed: 31677159
Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15718-23
pubmed: 15505215
Cancer Epidemiol. 2019 Feb;58:33-43
pubmed: 30448606
Nutr Hosp. 2020 Aug 27;37(4):786-793
pubmed: 32686451
Clin Res Hepatol Gastroenterol. 2017 Feb;41(1):93-102
pubmed: 27477122
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Metabolism. 2010 Aug;59(8):1231-9
pubmed: 20045534
Cancer Epidemiol Biomarkers Prev. 2021 Jun;30(6):1200-1207
pubmed: 33849965
Int J Obes Relat Metab Disord. 2001 Aug;25(8):1183-8
pubmed: 11477503
Cancer Causes Control. 2006 Dec;17(10):1291-7
pubmed: 17111261
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancer. 2022 Mar 15;128(6):1230-1241
pubmed: 34762301
Cancer Causes Control. 2015 Dec;26(12):1825-34
pubmed: 26450604
Int J Mol Sci. 2020 Nov 05;21(21):
pubmed: 33167521
Biometrics. 2000 Jun;56(2):455-63
pubmed: 10877304
BMC Public Health. 2021 Aug 4;21(1):1505
pubmed: 34348687
PLoS One. 2020 Oct 20;15(10):e0240413
pubmed: 33079929
Biol Sex Differ. 2016 Dec 9;7:66
pubmed: 27980714
Ann Intern Med. 1995 Mar 1;122(5):327-34
pubmed: 7847643
Cancer Epidemiol Biomarkers Prev. 2013 Aug;22(8):1383-94
pubmed: 23720402
Front Oncol. 2018 Dec 12;8:607
pubmed: 30631750
Arch Intern Med. 2000 Jul 24;160(14):2117-28
pubmed: 10904454
Int J Obes Relat Metab Disord. 2004 Apr;28(4):559-67
pubmed: 14770200
Int J Cancer. 2006 Mar 15;118(6):1496-500
pubmed: 16187280
Am J Clin Nutr. 2004 Mar;79(3):379-84
pubmed: 14985210
J Natl Cancer Inst. 1997 Jul 2;89(13):948-55
pubmed: 9214674
Br J Cancer. 2022 Mar;126(5):815-821
pubmed: 34853434
Cancer Causes Control. 2015 Feb;26(2):219-229
pubmed: 25430815
Gut. 2014 Mar;63(3):529-30
pubmed: 23903239
Metabolism. 2022 Dec;137:155326
pubmed: 36191637
Nutrients. 2016 Dec 15;8(12):
pubmed: 27983672
Liver Cancer. 2020 Jan;9(1):6-14
pubmed: 32071905
Cancer Prev Res (Phila). 2010 Dec;3(12):1608-20
pubmed: 20719902
Proc Nutr Soc. 2012 Feb;71(1):181-9
pubmed: 22051112
Clin J Gastroenterol. 2019 Aug;12(4):285-291
pubmed: 30788774
Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):352-8
pubmed: 18268119
BMC Public Health. 2023 Aug 29;23(1):1653
pubmed: 37644450
Int J Obes (Lond). 2013 Jun;37(6):783-9
pubmed: 22986684
CA Cancer J Clin. 2019 Mar;69(2):88-112
pubmed: 30548482
Lancet. 2005 Nov 5;366(9497):1640-9
pubmed: 16271645
J Clin Lipidol. 2017 Nov - Dec;11(6):1354-1360.e3
pubmed: 28942095
Cancer. 2006 Jul 1;107(1):28-36
pubmed: 16721800
Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):879-85
pubmed: 16702364
J Gastroenterol Hepatol. 2021 Oct;36(10):2834-2840
pubmed: 34033134
Am J Epidemiol. 2008 Mar 1;167(5):586-97
pubmed: 18270373
Ann Epidemiol. 2019 Jan;29:23-29.e1
pubmed: 30449532
Biosci Rep. 2017 Dec 12;37(6):
pubmed: 29026008
Biosci Rep. 2017 May 11;37(3):
pubmed: 28336766
Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):553-9
pubmed: 15066919
Br J Cancer. 2008 Aug 5;99(3):527-31
pubmed: 18628761
Oncotarget. 2015 Nov 10;6(35):38195-209
pubmed: 26472027
Epidemiology. 2016 May;27(3):423-32
pubmed: 26808598
Int J Cancer. 2019 Sep 1;145(5):1245-1253
pubmed: 30665257
Gut Liver. 2017 May 15;11(3):323-334
pubmed: 27890867
Eur J Clin Nutr. 2013 Dec;67(12):1298-302
pubmed: 24149442
J Natl Cancer Inst. 1999 Jul 7;91(13):1147-54
pubmed: 10393723
Cancer Res. 2016 Oct 15;76(20):6076-6083
pubmed: 27742674
Sci Rep. 2017 Dec 19;7(1):17807
pubmed: 29259258
Ann Oncol. 2012 Apr;23(4):843-52
pubmed: 21890910
Eur J Hum Genet. 2023 Aug;31(8):962-966
pubmed: 37161092
Cancer Epidemiol. 2022 Feb;76:102091
pubmed: 34998059
Int J Cancer. 2013 Feb 1;132(3):645-57
pubmed: 22618881